BIB vs. ARKG
BIB (ProShares Ultra Nasdaq Biotechnology) and ARKG (ARK Genomic Revolution Multi-Sector ETF) are both exchange-traded funds - BIB is a Leveraged Equities fund tracking the NASDAQ Biotechnology Index (200%), while ARKG is a Health & Biotech Equities fund actively managed by ARK. BIB is passively managed, while ARKG is actively managed. Over the past 10 years, BIB returned 9.71%/yr vs 8.67%/yr for ARKG. A 0.77 correlation means they provide meaningful diversification when combined. BIB charges 0.95%/yr vs 0.75%/yr for ARKG.
Performance
BIB vs. ARKG - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, BIB achieves a 12.50% return, which is significantly lower than ARKG's 24.30% return. Over the past 10 years, BIB has outperformed ARKG with an annualized return of 9.71%, while ARKG has yielded a comparatively lower 8.67% annualized return.
BIB
- 1D
- 1.97%
- 1M
- 9.49%
- YTD
- 12.50%
- 6M
- 8.62%
- 1Y
- 100.86%
- 3Y*
- 19.65%
- 5Y*
- -0.74%
- 10Y*
- 9.71%
ARKG
- 1D
- -1.07%
- 1M
- 17.41%
- YTD
- 24.30%
- 6M
- 19.48%
- 1Y
- 52.71%
- 3Y*
- 3.17%
- 5Y*
- -16.56%
- 10Y*
- 8.67%
BIB vs. ARKG - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
BIB ProShares Ultra Nasdaq Biotechnology | 12.50% | 59.21% | -9.84% | -1.06% | -28.85% | -6.02% | 39.79% | 46.71% | -24.93% | 40.49% |
ARKG ARK Genomic Revolution Multi-Sector ETF | 24.30% | 23.04% | -28.24% | 16.22% | -53.90% | -33.92% | 180.40% | 44.00% | -1.26% | 46.61% |
Correlation
The correlation between BIB and ARKG is 0.67, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.67 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.73 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.78 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.79 |
Correlation (All Time) Calculated using the full available price history since Oct 31, 2014 | 0.77 |
The correlation between BIB and ARKG shifts across timeframes, from 0.67 (1 year) to 0.79 (10 years), reflecting how their relationship changes across market environments.
BIB vs. ARKG - Sectors Allocation Comparison
Sectors
BIB
ARKG
Healthcare
Financial Services
Basic Materials
-
-
Communication Services
-
-
Consumer Cyclical
-
-
Consumer Defensive
-
-
Energy
-
-
Industrials
-
-
Real Estate
-
-
Technology
-
-
Utilities
-
-
Healthcare
BIB
ARKG
Financial Services
BIB
ARKG
Basic Materials
BIB
-
ARKG
-
Communication Services
BIB
-
ARKG
-
Consumer Cyclical
BIB
-
ARKG
-
Consumer Defensive
BIB
-
ARKG
-
Energy
BIB
-
ARKG
-
Industrials
BIB
-
ARKG
-
Real Estate
BIB
-
ARKG
-
Technology
BIB
-
ARKG
-
Utilities
BIB
-
ARKG
-
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BIB vs. ARKG — Risk / Return Rank
BIB
ARKG
BIB vs. ARKG - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for ProShares Ultra Nasdaq Biotechnology (BIB) and ARK Genomic Revolution Multi-Sector ETF (ARKG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BIB | ARKG | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.26 | ||
| Sortino ratioReturn per unit of downside risk | +1.16 | ||
| Omega ratioGain probability vs. loss probability | 1.36 | 1.22 | +0.14 |
| Calmar ratioReturn relative to maximum drawdown | 5.99 | 1.93 | +4.07 |
| Martin ratioReturn relative to average drawdown | 18.30 | 4.58 | +13.72 |
Loading charts...
Drawdowns
BIB vs. ARKG - Drawdown Comparison
The maximum BIB drawdown since its inception was -67.24%, smaller than the maximum ARKG drawdown of -83.59%. Use the drawdown chart below to compare losses from any high point for BIB and ARKG.
Loading charts...
Drawdown Indicators
| BIB | ARKG | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -67.24% | -83.59% | +16.35% |
Max Drawdown (1Y)Largest decline over 1 year | -16.92% | -27.51% | +10.59% |
Max Drawdown (3Y)Largest decline over 3 years | -45.30% | -51.96% | +6.66% |
Max Drawdown (5Y)Largest decline over 5 years | -65.86% | -80.18% | +14.32% |
Max Drawdown (10Y)Largest decline over 10 years | -66.20% | -83.59% | +17.39% |
Current DrawdownCurrent decline from peak | -17.29% | -67.78% | +50.49% |
Average DrawdownAverage peak-to-trough decline | -32.71% | -36.02% | +3.31% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.53% | 11.53% | -6.00% |
Volatility
BIB vs. ARKG - Volatility Comparison
The current volatility for ProShares Ultra Nasdaq Biotechnology (BIB) is 13.56%, while ARK Genomic Revolution Multi-Sector ETF (ARKG) has a volatility of 15.19%. This indicates that BIB experiences smaller price fluctuations and is considered to be less risky than ARKG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BIB | ARKG | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 13.56% | 15.19% | -1.63% |
Volatility (6M)Calculated over the trailing 6-month period | 31.65% | 30.91% | +0.74% |
Volatility (1Y)Calculated over the trailing 1-year period | 40.43% | 42.54% | -2.11% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 43.60% | 45.93% | -2.33% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 46.39% | 41.29% | +5.10% |
BIB vs. ARKG - Expense Ratio Comparison
BIB has a 0.95% expense ratio, which is higher than ARKG's 0.75% expense ratio.
Dividends
BIB vs. ARKG - Dividend Comparison
BIB's dividend yield for the trailing twelve months is around 0.55%, while ARKG has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
ARKG ARK Genomic Revolution Multi-Sector ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.62% | 0.85% | 3.14% | 0.82% | 1.34% |
BIB ProShares Ultra Nasdaq Biotechnology | 0.55% | 0.77% | 1.69% | 0.07% | 0.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Frequently Asked Questions
BIB and ARKG have a correlation of 0.67, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ARKG has higher volatility (15.19%) compared to BIB (13.56%). In terms of maximum drawdown, BIB dropped -67.24% vs ARKG's -83.59%.
On 10-year performance, BIB leads with 9.71% vs 8.67% for ARKG. On fees, ARKG is cheaper at 0.75% per year. On volatility, BIB has been the lower-risk option at 13.56%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 10-year period, BIB has performed better with a 9.71% return vs 8.67%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
ARKG is cheaper with a 0.75% expense ratio, compared with 0.95% for BIB.
BIB has the higher dividend yield at 0.55%, compared with 0.00% for ARKG.
BIB is categorized as Leveraged Equities, while ARKG is Health & Biotech Equities. They also come from different issuers: ProShares and ARK. Their fees differ too: 0.95% for BIB and 0.75% for ARKG.
BIB currently has the higher Sharpe Ratio (2.51 vs 1.25), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for BIB and ARKG
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer